The EGM is being convened to seek the approval of shareholders to certain resolutions which are intended to facilitate the migration of the Company's ordinary shares from the CREST System to the central securities depository ('CSD') system operated by
The approval of the Resolutions is necessary to ensure the continuation of electronic settlement of the Company's ordinary shares when traded on Euronext Growth and AIM and to remain eligible for continued admission to trading on those exchanges, which the Board believes is essential to the interests of the Company and its shareholders.
The circular, which includes the notice of the EGM, (the 'Circular') and a Form of Proxy will be posted to shareholders today. The Board strongly urges shareholders to review the contents of the Circular in their entirety, including the documents referred to therein, and to consider the Board's recommendation that shareholders vote in favour of the Resolutions.
The Circular, the Form of Proxy and copies of the documents referred to in the Circular are available to view on the Company's website, www.ovocabio.com, and will be available for inspection during normal working hours on any business day from the date of this announcement until the EGM at the
COVID-19 Guidelines
The well-being of our Shareholders and our people is a primary concern for the Directors. We are closely monitoring the COVID-19 situation and any advice by the
The Company continues to monitor the impact of COVID-19 and any relevant updates regarding the EGM, including any changes to the arrangements outlined in the Circular, will be announced via a
It will be possible to listen to the proceedings of the EGM remotely by utilising a teleconference facility provided by the Company for this purpose. To join the teleconference facility, and receive dial-in access numbers and participant passcodes, please register on the Company website at www.ovocabio.com before
All shareholders will be able to submit questions in advance of the EGM in writing by email to the Company Secretary at info@ovocabio.com to be received no later than
Terms used but not defined in this announcement have the same meaning as set out in the Circular.
Contact:
Tel: +353 1 661 9819
Email: info@ovocabio.com
About
The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in
(C) 2021 Electronic News Publishing, source